<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579110</url>
  </required_header>
  <id_info>
    <org_study_id>ZXMZ2012</org_study_id>
    <nct_id>NCT01579110</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.</brief_title>
  <official_title>Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Levamisole plus prednisone can further
      improve the efficacy，extend the remission duration and reduce the dosage of prednisone for
      newly diagnosed warm antibody autoimmune hemolytic anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first line treatment in warm antibody autoimmune hemolytic anemia (WAIHA) is the
      glucocorticoid, but most of the patients, hemolytic events will frequently recurred after end
      of treatment or during the gradual reduction in dosage of prednisolone. As a result, many
      patients will finally accepted long-term glucocorticoids or other immunosuppressive drugs.
      How to reduce the relapse rate of AIHA is still difficult. Levamisole（LMS）is a
      immunoregulator.Recent studies have shown LMS has been widely used to treat autoimmune
      diseases ,such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic
      thrombocytopenic purpura. The purpose of this study is to determine whether LMS combined with
      prednisolone can further improve the efficacy，extend the remission duration and reduce the
      dosage of prednisone for newly diagnosed warm antibody autoimmune hemolytic anemia.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients in each group in complete or partial remission</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anemia</condition>
  <condition>Anemia, Hemolytic</condition>
  <condition>Anemia, Hemolytic, Autoimmune</condition>
  <condition>Hemolysis</condition>
  <condition>Hematologic Diseases</condition>
  <condition>Autoimmune Diseases</condition>
  <condition>Immune System Diseases</condition>
  <condition>Pathologic Processes</condition>
  <arm_group>
    <arm_group_label>prednisolone + levamisole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levamisole</intervention_name>
    <description>Levamisole 2.5mg/kg(every other day) over six months.
Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.</description>
    <arm_group_label>prednisolone + levamisole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.</description>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and biochemical signs of hemolytic anaemia

          -  Positive Coombs test with anti-IgG or and with anti-CD3d

          -  Newly diagnosed Warm Autoimmune Hemolytic Anemia

          -  Adequate contraceptive measures for women of childbearing potential

          -  informed consent signed

        Exclusion Criteria:

          -  Active infection which requires antibiotic treatment

          -  Pregnant or lactating women

          -  Epilepsy and mental illness

          -  Kidney and liver function abnormal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhou Zheng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood Diseases Hospital Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood Diseases Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>TianJin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yizhou Zheng</investigator_full_name>
    <investigator_title>Vice director of the therapeutic centre of anemic diseases</investigator_title>
  </responsible_party>
  <keyword>autoimmune hemolytic anemia</keyword>
  <keyword>hemolytic anemia</keyword>
  <keyword>Levamisole</keyword>
  <keyword>Treatment of autoimmune hemolytic anemia</keyword>
  <keyword>warm antibody dependant autoimmune hemolytic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Immune System Diseases</mesh_term>
    <mesh_term>Pathologic Processes</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Autoantibodies</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

